T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Becton Dickinson
BDX
|
+$3.46B |
| 2 |
UnitedHealth
UNH
|
+$2.79B |
| 3 |
Salesforce
CRM
|
+$2.38B |
| 4 |
Sherwin-Williams
SHW
|
+$1.41B |
| 5 |
Philip Morris
PM
|
+$1.34B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$4.44B |
| 2 |
Alphabet (Google) Class C
GOOG
|
+$2.97B |
| 3 |
GE Aerospace
GE
|
+$2.3B |
| 4 |
HCA Healthcare
HCA
|
+$2.17B |
| 5 |
American International
AIG
|
+$1.68B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 26.68% |
| 2 | Healthcare | 19.49% |
| 3 | Consumer Discretionary | 13.07% |
| 4 | Financials | 11.17% |
| 5 | Communication Services | 8.7% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
726
Gartner
IT
$11.3B
| $80.1M | 0.01% |
331,303
-19,396
| -6% | -$5.16M |
|
727
AMN Healthcare
AMN
$1.32B
| $79.7M | 0.01% |
726,164
-77,438
| -10% | -$7.67M |
|
728
Embecta
EMBC
$286M
| $79.5M | 0.01% |
3,141,266
+692,770
| +28% | +$20M |
|
729
Exponent
EXPO
$3.21B
| $79.5M | 0.01% |
869,262
-88,610
| -9% | -$8.35M |
|
|
RAPT
730
DELISTED
RAPT Therapeutics
RAPT
| $79.1M | 0.01% |
541,835
+44,997
| +9% | +$6M |
|
731
CACI
CACI
$14.9B
| $79M | 0.01% |
280,485
+1,767
| +0.6% | +$492K |
|
|
AMED
732
DELISTED
Amedisys
AMED
| $78.4M | 0.01% |
746,268
-168,412
| -18% | -$21.5M |
|
|
VBTX
733
DELISTED
Veritex Holdings
VBTX
| $77.3M | 0.01% |
2,641,794
+645,296
| +32% | +$21.5M |
|
734
Factset
FDS
$10B
| $77.3M | 0.01% |
200,958
+42,946
| +27% | +$16.8M |
|
735
Brookfield
BN
$109B
| $77.3M | 0.01% |
3,224,694
-990,009
| -23% | -$26.5M |
|
736
Encore Capital Group
ECPG
$2.14B
| $77M | 0.01% |
1,332,531
-86,785
| -6% | -$5.14M |
|
737
Dover
DOV
$27.9B
| $76.9M | 0.01% |
633,467
+12,369
| +2% | +$1.67M |
|
738
Copart
CPRT
$27.1B
| $76.8M | 0.01% |
2,826,768
-297,172
| -10% | -$8.46M |
|
739
Edwards Lifesciences
EW
$53.5B
| $76.7M | 0.01% |
806,914
-83,655
| -9% | -$8.66M |
|
740
Essent Group
ESNT
$6.18B
| $76.5M | 0.01% |
1,967,824
-282,571
| -13% | -$11.5M |
|
741
FTI Consulting
FCN
$4.18B
| $76.3M | 0.01% |
421,806
-65,507
| -13% | -$10.8M |
|
|
BHVN
742
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $76M | 0.01% |
521,580
+5,809
| +1% | +$742K |
|
743
Li Auto
LI
$12B
| $75.7M | 0.01% |
1,976,360
-47,980
| -2% | -$1.28M |
|
744
Kearny Financial
KRNY
$604M
| $75.7M | 0.01% |
6,812,187
-19,453
| -0.3% | -$233K |
|
745
CALL
iShares US Home Construction ETF
ITB
$2.37B
| $75.7M | 0.01% |
+1,441,100
| New | +$82.3M |
|
746
LCI Industries
LCII
$2.61B
| $75.6M | 0.01% |
675,692
-49,849
| -7% | -$5.45M |
|
747
American Water Works
AWK
$27.1B
| $75.4M | 0.01% |
506,812
-556,471
| -52% | -$84.8M |
|
|
ONC
748
BeOne Medicines Ltd
ONC
$40.2B
| $74.8M | 0.01% |
462,144
-64,352
| -12% | -$10.1M |
|
749
Trimble
TRMB
$13B
| $74.1M | 0.01% |
1,272,495
-318,806
| -20% | -$20.9M |
|
|
FBMS
750
DELISTED
The First Bancshares, Inc.
FBMS
| $73.8M | 0.01% |
2,582,066
-193
| -0% | -$5.99K |
|
Similar funds
T. Rowe Price Associates's Q2 2022 Portfolio in Review
As of Q2 2022, T. Rowe Price Associates held 3,063 positions worth $791B, down 20% from $992B the previous quarter. Its ten largest holdings account for 26% of the portfolio.
T. Rowe Price Associates's Q2 2022 filing shows 88 new, 1,490 increased, 1,207 reduced and 101 closed positions. Its largest new stake was ESAB: 6,073,363 shares worth $266M. The largest sale was Meta Platforms (Facebook), an estimated $4.44B.
By sector, the portfolio is most concentrated in Technology at 27% of assets, down from 27% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q2 2022 buy was ESAB: 6,073,363 shares worth $266M.
- T. Rowe Price Associates added most to Becton Dickinson in Q2 2022, an estimated $3.46B increase.
- T. Rowe Price Associates's biggest Q2 2022 reduction was Meta Platforms (Facebook), cutting an estimated $4.44B.
- T. Rowe Price Associates fully exited Ortho Clinical Diagnostics Holdings plc Ordinary Shares in Q2 2022, selling an estimated $364M.
- T. Rowe Price Associates's ten largest holdings make up 26% of its $791B portfolio in Q2 2022.
- T. Rowe Price Associates opened 88 new positions and closed 101 in Q2 2022.
- T. Rowe Price Associates's portfolio value fell 20% quarter-over-quarter to $791B.
Based on T. Rowe Price Associates's 13F filing for Q2 2022, filed 15 Aug 2022.